Proffered Paper session 1
Invited discussant abstract: 183O
Date
23 May 2020Session
Proffered Paper session 1Presenters
Dario TrapaniAuthors
D. TrapaniAuthor affiliations
- Istituto Europeo di Oncologia, 20141 - Milan/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
139O - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
140O - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
Presenter: Jean-Pierre Ayoub
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
183O - Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)
Presenter: Antonio Di Meglio
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts: 139O and 140O
Presenter: Suzette Delaloge
Session: Proffered Paper session 1
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.